Esperion announced a new campaign to educate patients about the cardiovascular risks of uncontrolled or under-controlled LDL cholesterol.
Tag Archive for: Esperion
The FDA’s busy March continues with six target action dates remaining on the calendar. Over the next two weeks, the regulator will decide on investigational therapies for Duchenne muscular dystrophy, chronic kidney disease anemia, a rare metabolic disorder and more.